Publication:
Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma

Simple item page
dc.contributor.coauthorPatel, Roshal R.
dc.contributor.coauthorTang, Christine
dc.contributor.coauthorOnstad, Michaela
dc.contributor.coauthorNagarajan, Priyadharsini
dc.contributor.coauthorPatel, Sapna P.
dc.contributor.coauthorWelsh, James W.
dc.contributor.coauthorLin, Lilie L.
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorSezen, Duygu
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T22:58:53Z
dc.date.issued2021
dc.description.abstractA 73-year-old woman with metastatic vaginal mucosal melanoma that had progressed on ipilimumab and nivolumab experienced clinical and radiographic complete response to dual checkpoint inhibitor immunotherapy given in combination with high-dose plus low-dose radiation. General characteristics and treatment options in this disease are highlighted.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue3
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipVarian Medical Systems
dc.description.sponsorshipNational Cancer Institute (Cancer Center Support Core Grant) [P30 CA016672] The patient was treated on a trial supported by Varian Medical Systems and the National Cancer Institute (via Cancer Center Support Core Grant P30 CA016672 to The University of Texas MD Anderson Cancer Center) .
dc.description.volume161
dc.identifier.doi10.1016/j.ygyno.2021.03.017
dc.identifier.eissn1095-6859
dc.identifier.issn0090-8258
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85103319914
dc.identifier.urihttps://doi.org/10.1016/j.ygyno.2021.03.017
dc.identifier.urihttps://hdl.handle.net/20.500.14288/7786
dc.identifier.wos654681200003
dc.keywordsVaginal mucosal melanoma
dc.keywordsLow dose radiation
dc.keywordsAbscopal effect
dc.keywordsImmunotherapy primary malignant-melanoma
dc.keywordsMucosal melanoma
dc.keywordsAbscopal responses
dc.keywordsPhase-II
dc.keywordsIpilimumab
dc.keywordsManagement
dc.keywordsSafety
dc.keywordsSurvival
dc.keywordsEfficacy
dc.keywordsTherapy
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofGynecologic Oncology
dc.subjectOncology
dc.subjectObstetrics
dc.subjectGynecology
dc.titleImmunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorSezen, Duygu
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Collections

Publications without Fulltext